2vgz
From Proteopedia
| Line 4: | Line 4: | ||
|PDB= 2vgz |SIZE=350|CAPTION= <scene name='initialview01'>2vgz</scene>, resolution 2.30Å | |PDB= 2vgz |SIZE=350|CAPTION= <scene name='initialview01'>2vgz</scene>, resolution 2.30Å | ||
|SITE= <scene name='pdbsite=AC1:Iod+Binding+Site+For+Chain+A'>AC1</scene> | |SITE= <scene name='pdbsite=AC1:Iod+Binding+Site+For+Chain+A'>AC1</scene> | ||
| - | |LIGAND= <scene name='pdbligand=IOD:IODIDE ION'>IOD</scene> | + | |LIGAND= <scene name='pdbligand=IOD:IODIDE+ION'>IOD</scene>, <scene name='pdbligand=LLP:2-LYSINE(3-HYDROXY-2-METHYL-5-PHOSPHONOOXYMETHYL-PYRIDIN-4-YLMETHANE)'>LLP</scene> |
|ACTIVITY= | |ACTIVITY= | ||
|GENE= | |GENE= | ||
| + | |DOMAIN= | ||
| + | |RELATEDENTRY= | ||
| + | |RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2vgz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2vgz OCA], [http://www.ebi.ac.uk/pdbsum/2vgz PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2vgz RCSB]</span> | ||
}} | }} | ||
| Line 27: | Line 30: | ||
[[Category: Rossi, F.]] | [[Category: Rossi, F.]] | ||
[[Category: Walsh, M A.]] | [[Category: Walsh, M A.]] | ||
| - | [[Category: IOD]] | ||
[[Category: alternative splicing]] | [[Category: alternative splicing]] | ||
[[Category: aminotransferase]] | [[Category: aminotransferase]] | ||
| Line 38: | Line 40: | ||
[[Category: transit peptide]] | [[Category: transit peptide]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 05:12:12 2008'' |
Revision as of 02:12, 31 March 2008
| |||||||
| , resolution 2.30Å | |||||||
|---|---|---|---|---|---|---|---|
| Sites: | |||||||
| Ligands: | , | ||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
CRYSTAL STRUCTURE OF HUMAN KYNURENINE AMINOTRANSFERASE II
Overview
Kynurenic acid is an endogenous neuroactive compound whose unbalancing is involved in the pathogenesis and progression of several neurological diseases. Kynurenic acid synthesis in the human brain is sustained by the catalytic activity of two kynurenine aminotransferases, hKAT I and hKAT II. A wealth of pharmacological data highlight hKAT II as a sensible target for the treatment of neuropathological conditions characterized by a kynurenic acid excess, such as schizophrenia and cognitive impairment. We have solved the structure of human KAT II by means of the single-wavelength anomalous dispersion method at 2.3-A resolution. Although closely resembling the classical aminotransferase fold, the hKAT II architecture displays unique features. Structural comparison with a prototypical aspartate aminotransferase reveals a novel antiparallel strand-loop-strand motif that forms an unprecedented intersubunit beta-sheet in the functional hKAT II dimer. Moreover, the N-terminal regions of hKAT II and aspartate aminotransferase appear to have converged to highly similar although 2-fold symmetry-related conformations, which fulfill the same functional role. A detailed structural comparison of hKAT I and hKAT II reveals a larger and more aliphatic character to the active site of hKAT II due to the absence of the aromatic cage involved in ligand binding in hKAT I. The observed structural differences could be exploited for the rational design of highly selective hKAT II inhibitors.
About this Structure
2VGZ is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
Reference
Crystal Structure of Human Kynurenine Aminotransferase II, a Drug Target for the Treatment of Schizophrenia., Rossi F, Garavaglia S, Montalbano V, Walsh MA, Rizzi M, J Biol Chem. 2008 Feb 8;283(6):3559-66. Epub 2007 Dec 5. PMID:18056996
Page seeded by OCA on Mon Mar 31 05:12:12 2008
